cagrilintide 5mg semaglutide 5mg + 5 mg/5 mg – Peptide Cart UPB CagriSema 5MG/5MG

Clinical trial data shows cagrilintide has a higher incidence (4060%) and greater severity of nausea compared to semaglutide (3045%) or tirzepatide (2535%)

11.8% Avg Body Weight Loss* 68 Week Phase 3 Trial 1x Weekly Injection 2026 Expected FDA Decision Coming Soon A novel amylin analogue offering a different approach to weight management

Diarrhea Diarrhea might seem contradictory given the constipation discussion, but GI motility disruption can manifest in either direction depending on the individual

Most people achieve 20-30 pounds of weight loss over 12-18 months on cagrilintide alone, with combination therapy producing 40-60+ pounds lost